Riyadh: The Saudi Food and Drug Authority (SFDA) concluded the Generic Drugs Conference, held under the theme 'Empowering Local Pharmaceutical Manufacturing,' at its headquarters in Riyadh on Tuesday. The conference was attended by SFDA Chief Executive Officer Dr. Hisham Aljadhey, along with representatives of regulatory bodies, pharmaceutical companies, healthcare providers, and a number of investors and academic experts.
According to Saudi Press Agency, the agenda featured scientific sessions and panel discussions addressing the future of the pharmaceutical sector amid rapid technological developments that are reshaping the global healthcare and pharmaceutical landscape. Discussions focused on global best practices and ways to align the sector with the strategic objectives of Saudi Vision 2030.
The conference also highlighted significant investment opportunities within the Kingdom, particularly the growing government incentives aimed at supporting both local and foreign investors. These efforts contribute to strengthening Saudi Arabia's position within the global pharmaceutical industry.
Several key themes were addressed, including investment opportunities and government incentives, as well as the role of hospital drug lists and procurement policies in promoting the use of generic drugs in accordance with approved standards. Participants also stressed the importance of coordination among regulatory authorities to build public and clinical confidence in generic medicines.
During the closing session, speakers emphasized the importance of continued collaboration between the SFDA, the pharmaceutical industry, and healthcare providers to foster innovation, accelerate patient access to essential medicines, and benefit from industry feedback in developing regulations that ensure the sustainability of quality and safety standards.
By showcasing investment opportunities, the conference underscored the pharmaceutical sector's role in supporting sustainable healthcare. It also reaffirmed the SFDA's position as a globally recognized scientific authority and highlighted its strategic role in diversifying the national economy and advancing the Kingdom's healthcare and pharmaceutical ecosystems.